Zentalis Pharmaceuticals, Inc.
ZNTL
$4.14
-$0.01-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -33.76% | -33.76% | -33.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -33.76% | -33.76% | -33.76% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -33.76% | -33.76% | -33.76% |
| SG&A Expenses | -62.19% | -62.77% | 8.18% | 11.83% | 28.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.68% | -45.18% | -28.65% | -24.96% | -11.06% |
| Operating Income | 29.28% | 25.46% | 27.66% | 23.34% | 6.75% |
| Income Before Tax | 44.87% | 17.55% | 16.51% | 16.15% | -2.09% |
| Income Tax Expenses | 1,552.94% | 149.72% | -183.00% | -176.07% | 106.01% |
| Earnings from Continuing Operations | 44.63% | 17.37% | 16.74% | 16.40% | -2.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -100.00% | -100.00% |
| Net Income | 44.63% | 17.35% | 16.72% | 16.37% | -2.41% |
| EBIT | 29.28% | 25.46% | 27.66% | 23.34% | 6.75% |
| EBITDA | 29.16% | 25.34% | 27.64% | 23.36% | 6.74% |
| EPS Basic | 44.78% | 18.15% | 17.51% | 17.08% | 6.21% |
| Normalized Basic EPS | 35.01% | 18.50% | 17.48% | 16.96% | 2.07% |
| EPS Diluted | 44.78% | 18.22% | 17.58% | 17.14% | 6.27% |
| Normalized Diluted EPS | 35.01% | 18.53% | 17.51% | 16.98% | 2.10% |
| Average Basic Shares Outstanding | 0.34% | 1.11% | 1.13% | 0.94% | 4.38% |
| Average Diluted Shares Outstanding | 0.34% | 1.00% | 1.02% | 0.84% | 4.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |